China Resources Sanjiu Medical & Pharmaceutical's (SHE:000999) attributable profit rose 28% to 2.40 billion yuan in the first half from 1.88 billion yuan in the year-ago period.
Earnings per share at the drug company increased 27% to 1.87 yuan from 1.47 yuan in the previous year, according to a Friday filing by parent China Resources Pharmaceutical (HKG:3320) with the Hong Kong Stock Exchange.
Revenue grew 7.3% to 14.11 billion yuan from 13.15 billion yuan a year earlier.
CR Sanjiu's shares rose nearly 3% in recent trading.
Price (HKD): $43.95, Change: $+1.2, Percent Change: +2.86%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments